Progyny director exercises options, sells 11.5K shares

A Progyny director exercised 22,000 options and disposed of all resulting shares through withholding and market sales on September 10, 2026.

Rhea-AI Filing Summary

Progyny, Inc. (PGNY) director Kevin K. Gordon exercised options for 22,000 shares of common stock on September 10, 2026 at an exercise price of $13.00 per share, receiving 22,000 shares. On the same date, 10,500 shares were delivered or withheld to cover the exercise price or tax liability at $27.24 per share, and 11,500 shares were sold at a weighted average price within a range of $26.99 to $27.24 per share. The options exercised were reported as fully vested, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider GORDON KEVIN K

Role Director

Sold 11,500 shs ($321K)

Approx. gross sale proceeds $321K

Approx. exercise cost $286K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	22,000	$0.00	$0.00
Exercise	Common Stock	22,000	$13.00	$286K
Exercise Price or Tax Liability	Common Stock	10,500	$27.24	$286K
Sale	Common Stock F1	11,500	$27.9442	$321K

Holdings After Transaction: Stock Option (Right to Buy) — 22,000 contracts (Direct); Common Stock — 6,792 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
2. F2. The shares are fully vested.

Key Figures

Options exercised: 22,000 shares Option exercise price: $13.00 per share Shares delivered/withheld: 10,500 shares +3 more

6 metrics

Options exercised 22,000 shares Stock options exercised by Kevin K. Gordon on September 10, 2026

Option exercise price $13.00 per share Exercise price for 22,000 options exercised on September 10, 2026

Shares delivered/withheld 10,500 shares Shares delivered or withheld for exercise price or tax liability on September 10, 2026

Delivery/withholding price $27.24 per share Price for 10,500 shares delivered or withheld on September 10, 2026

Shares sold 11,500 shares Common shares sold by Kevin K. Gordon on September 10, 2026

Sale price range $26.99–$27.24 per share Price range for 11,500 shares sold at a weighted average price

Key Terms

weighted average price, fully vested

2 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested financial

"The shares are fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Progyny (PGNY) report for Kevin K. Gordon?

Progyny reported that director Kevin K. Gordon exercised 22,000 stock options on September 10, 2026, acquiring 22,000 shares of common stock at an exercise price of $13.00 per share, then disposing of all 22,000 shares through share withholding and market sales.

How many Progyny (PGNY) options did Kevin K. Gordon exercise and at what price?

Kevin K. Gordon exercised options covering 22,000 shares of Progyny common stock at an exercise price of $13.00 per share on September 10, 2026, receiving 22,000 shares upon exercise.

How many Progyny (PGNY) shares were sold by Kevin K. Gordon and at what price range?

Kevin K. Gordon sold 11,500 shares of Progyny common stock on September 10, 2026 at a weighted average price, with individual trade prices ranging from $26.99 to $27.24 per share.

How many Progyny (PGNY) shares were used to cover exercise price or taxes for Kevin K. Gordon?

In connection with the option exercise, 10,500 shares of Progyny common stock were delivered or withheld on September 10, 2026 to pay the exercise price or tax liability, at $27.24 per share.

Were the exercised Progyny (PGNY) options fully vested for Kevin K. Gordon?

Yes. The filing states that the 22,000 options exercised by Kevin K. Gordon on September 10, 2026 were fully vested at the time of exercise.

Was Kevin K. Gordon’s Progyny (PGNY) trade made under a Rule 10b5-1 plan?

No. The filing does not report use of a Rule 10b5-1 trading plan; the document-level checkbox for such a plan is not selected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 05:54 PM Accepted by SEC EDGAR 09/14/2026 - 05:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GORDON KEVIN K

(Last) (First) (Middle)

C/O PROGYNY, INC.

1359 BROADWAY, 2ND FLOOR

(Street)

NEW YORK NEW YORK 10018

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Progyny, Inc. [ PGNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		M		22,000	A	$13	28,792	D
Common Stock	09/10/2026		F		10,500	D	$27.24	18,292	D
Common Stock	09/10/2026		S		11,500	D	$27.9442(1)	6,792	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13	09/10/2026		M			22,000	(2)	10/11/2029	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

2. The shares are fully vested.

Remarks:

	/s/ Mark Livingston, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)